Future-Oriented Partnership: Bayer and Kadans Science Partner Join Forces to Shape the Life Sciences Campus at Berlin's Nordhafen
The Bayer campus in Berlin is establishing itself as a leading hub for healthcare innovation, becoming the top destination in Germany and Europe.
Berlin 30 March 2026– Bayer and Kadans Science Partner enter into a partnership to advance the development of a Life Sciences Campus in the heart of Berlin. The campus is intended to serve as a center of excellence for science, technology, and innovation, delivering novel therapies, modalities, and digital health solutions to address unmet patient needs.
As part of this partnership, both parties will closely collaborate to further develop the Life Sciences Campus on prime land plots at Nordhafen / Fennstraße in Berlin-Mitte. A key element of this partnership is the creation of modern laboratory and office spaces for companies, research institutions, university spin-offs, founders, and start-ups in the life sciences sector. This will create a robust innovation ecosystem that closely links research, development, production, and market introduction.
“We believe that our partnership will contribute to the further development of the Life Sciences Campus at Nordhafen and promote the targeted expansion of the ecosystem as well as the networking of companies, start-ups, and research institutions,” says Bettina von Streit, Site Manager for Bayer Pharmaceuticals in Berlin. “This initiative will not only significantly strengthen the competitiveness of the healthcare industry but also provide optimal conditions for companies from around the world to scale their research and development efforts at one of the most attractive locations in Europe,” Bettina von Streit adds.
Chiel van Dijen, International Head of Operations at Kadans Science Partner states: “We look forward to our collaboration with Bayer to strengthen the life sciences ecosystem in Berlin. We are fully committed to enabling innovative companies to establish themselves and thrive within this emerging community. Our partnership with Bayer offers a unique opportunity to not only create sustainable new research facilities and strengthen our European network, but also to help drive the development of a world-leading life sciences cluster in the German capital.”
The planned collaboration marks another milestone in the creation of a leading ecosystem for healthcare innovation and serves as the starting point for an ambitious project.
